/* */ PELVIPHARM - SPECIALIZED PRECLINICAL EXPERTISE in male and female sexual functions and diseases of the lower urinary tract
Receive our news


July 26th - 2011

Recently accepted paper in Eur Urol as platinium priority

Combination of BAY 60-4552 and vardenafil exerts proerectile facilitator effects in rats with cavernous nerve injury: A proof of concept study for the treatment of PDE5 inhibitor failure.
Oudot A., Behr-Roussel D., Poirier S., Sandner P., Bernabé J., Alexandre L., Giuliano F.
Eur. Urol. - 2011 Nov : 60(5):1020-1026.

June 29th - 2011

AUA education and research, Inc. congratulates Delphine Behr-Roussel

American urological association education and research, Inc. congratulates Delphine Behr-Roussel for her presentation at AUA 2011 in Washington, DC, USA, 14 -19 may 2011.

The abstract “A new Experimental Rat Model of Erectile Dysfunction and Lower Urinary Tract Symptoms Associated with Benign Prostate Hyperplasia: The Testosterone-supplemented Spontaneously Hypertensive Rat” was selected to be presented as a part of an overall scientific lecture on BPH at the 2011 Best of AUA/JUA Annual Meeting to be held in Tokyo, Japan, October 1-2, 2011.
This abstract will be presented by Dr. Yoshiyuki Kojima to young Japanese residents.Behr_Roussel_AUA_06_2011.jpg


May 30th - 2011

Recently accepted paper in Curr Opin Urol

Botulinum neurotoxin A for male lower urinary tract symptoms.
Chartier-Kastler E, Mehnert U, Denys P, Giuliano F.
Curr Opin Urol. 2011 Jan;21(1):13-21. Review.

(Erratum in: Curr Opin Urol. 2011 May;21(3):265. Dosage error in article text.)

May 24th - 2011

Take Home Message on “Sexual function and dysfunction” session - AUA 2011

Pelvipharm is quoted in the “Take Home Messages” on “Sexual function and dysfunction” presented by Gerald Brock at the AUA (American Urological Association) in Washington, DC the may 17th, 2011.

Pelvipharm’s study “Experimental evidence that a combination of sGC stimulator BAY 60-4552 and PDE5 inhibitor vardenafil might salvage patients with insufficient response to PDE5 inhibitors after cavernous nerve injury” was highlighted as the most innovative research in the “Sexual function and dysfunction”session.

January 11th - 2011

Future presentation at the EAU 2011

Pelvipharm at the EAU (European Association of Urology) in Vienna, Austria, 18 - 22 March 2011.

Pelvipharm will present 1 Poster:

Please come and see us, we will be happy to discuss our results with you and potential applications for you.


Page 13 / 22     Previous      1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  Next 
TEL +331 704 293 39
FAX + 331 704 295 10